Large granular lymphocyte (LGL) leukemia is a T or NK clonal disorder characterized by the tissue invasion of marrow, spleen and liver. Clinical presentation is dominated by recurrent infections associated with neutropenia, anemia, splenomegaly and autoimmune diseases, particularly rheumatoid arthritis.1, 2, 3, 4 Recently, STAT3 and STAT5 mutations have been detected in T-LGL and in NK-LGL leukemias.5, 6, 7, 8 These somatic mutations, coupled to other intrinsic and extrinsic mechanisms, are likely to induce constitutive activation of the JAK/STAT pathway thus contributing to maintenance of leukemic LGL survival.9 These findings strongly suggest a common specific pathogenic pattern in T-LGL and NK-LGL leukemias and provide justification for consideration of the same treatment options. Indications for treatment are severe or symptomatic neutropenia, symptomatic or transfusion-dependent anemia or associated autoimmune diseases requiring therapy. There is no standard treatment for patients with LGL leukemia. All the largest series published in the literature (collecting data on more than 40 patients) are retrospective. Data are very heterogeneous and treatment outcome per single agent is available for very few patients. Immunosuppressive therapy remains the foundation of treatment including single agents that is, methotrexate, oral cyclophosphamide or cyclosporine. On the basis of an initial study showing very good overall response rate (ORR) using methotrexate, this drug has remained the most recommended option in LGL leukemia.10 Oral low dose cyclophosphamide was first used in pure red cell aplasia associated with LGL leukemia.11, 12 In a French series, cyclophosphamide was shown to be also efficient in neutropenic patients and for those who failed methotrexate.13 Those results suggested that cyclophosphamide used as first-line therapy could be an interesting alternative to methotrexate.
In this letter, we describe the encouraging results of cyclophosphamide used in a series of 45 previously untreated LGL leukemia patients. Patients suffering from LGL leukemia and treated with cyclophosphamide as first-line therapy were included in this retrospective study. Patients were screened from the Italian, French and USA Penn State registries. Patients gave their informed consent for data collection. The diagnosis of LGL leukemia was based on a chronic LGL peripheral blood expansion (>0.5 × 109/l), usually lasting for more than 6 months. Criteria for T-LGL leukemia included expression of LGL surface markers compatible with a typical T-cell (commonly αβ+ or γδ+/CD3+/CD8+/CD57+ and/or CD16+) phenotype associated with clonal rearrangement of TCRγ gene using PCR or clonal Vβ expression using flow cytometry. Criteria for NK-LGL lymphocytosis/chronic NK-LGL leukemia included expression of LGL surface markers compatible with a NK-cell (commonly CD3−/CD8+/CD16+ and/or CD56+) phenotype with more than 0.75 × 109/l circulating cells.14, 15 Response to treatment was determined periodically on blood cell count and only best response was taken into account. Hematological complete response (CR) was defined by a normal blood count (hemoglobin (Hb)>12g/dl, platelets>150 × 109/l, absolute neutrophil count (ANC)>1.5 × 109/l and lymphocytosis<4 × 109/l) and LGL peripheral count in a normal range (<0.3 × 109/l). Molecular CR was based on hematological CR associated with a negative PCR analysis for CD3+ cases. Hematologic partial response was defined as an improvement in blood count specified as follows: ANC increasing more than 50% and reaching more than 0.5 but less than 1.5 × 109/l; Hb level increasing more than 2 g/dl and transfusion independent without reaching 12 g/dl level. Treatment failure was defined as a progressive disease (worsening of cytopenia or organomegaly) or a stable disease (none of the later given criteria met). Some patients received cyclophosphamide because of symptoms not related to cytopenia. For those patients, response criteria included clinical symptom resolution. Patients who received prednisone, granulocyte colony-stimulating factor or erythropoiesis-stimulating agent before or at the same time of cyclophosphamide were included in this retrospective study. For the descriptive analysis, qualitative variables were described using numbers and percentage, whereas medians and extremes were used to describe quantitative analyses. Qualitative variables were compared using χ2 or Fisher’s test.
A total of 45 patients treated with cyclophosphamide as a first-line therapy for LGL leukemia from 1989 to 2012 were retrospectively included in this series. Clinical characteristics are described in Table 1. Starting doses were as follows: 100 mg/day (n=36), 50 to 75 mg/day (n=8) taken orally and 1 g IV/month (n=1). Median time from diagnosis to treatment was 3 months (range, 0–55). Treatment was initiated because of severe isolated neutropenia (n=16, 36%), neutropenia and anemia (n=2, 4%), transfusion-dependent anemia (n=15, 33%) and thrombocytopenia (n=5, 11% including three cases of idiopathic thrombopenic purpura). Seven non-cytopenic patients (15%) were treated for disease-associated LGL leukemia: neuropathy (n=3), vasculitis (n=1) and constitutive symptoms (n=3). ORR was 71% (32/45): there were 21 CR (47%) including three molecular responses (mCR) and 11 (24%) partial responses. ORR was 72% versus 68% for T-LGL and NK-LGL subtype, and 72% versus 67% for neutropenic and anemic patients, respectively (P=not significant). Patients treated for symptoms related to LGL leukemia had a 94% ORR (6/7). Eighteen patients (40%) were initially co-treated with prednisone and no significant impact was found for the response to cyclophosphamide (P=0.31). As well as, concomitant granulocyte colony-stimulating factor administration with cyclophosphamide did not influence the time to response and the ORR. The median time to reach best response was 4 months (range 0.8–21) and patients were treated for a median time of 6.4 months (range 0.5–33). Evidence of clinico-biological improvement was systematically observed within the 4 months following treatment initiation. Therefore, we assume that cyclophosphamide should be given for at least 4 months before changing drug regimen. Median treatment duration was 8.5 months (range 3.4–33) for responders, except one patient who received several courses of cyclophosphamide for 7 years. With a median time follow-up of 35 months (range 3.8–277), four out of the 32 responders relapsed (13%): one of these patients responded again to a short course of cyclophosphamide and was maintained subsequently on cyclosporine decided thereafter. The three others were switched to either methotrexate or cyclosporine. Eight patients experienced grade 1–2 toxicities (18%). Only three patients (7%) stopped treatment: one because of worsened anemia and two because of febrile neutropenia not obviously related to hematological toxicity. One patient experienced temporary worsening of anemia without stopping therapy.
We previously mentioned that cyclophosphamide induces a very good ORR in LGL leukemia in de novo or relapsing patients.14 The ORR of 71% described in our series confirmed and emphasized what has been reported in the literature with a total of 25 responders out of 38 patients treated as first line with cyclophosphamide (66% ORR) (Table 2).11, 12, 13, 17, 18 We show that cyclophosphamide compares favorably to methotrexate given as a first-line therapy. In 1993, Loughran et al.10 reported a 60% ORR in a prospective series of 10 patients receiving methotrexate at a weekly dose of 10 mg/m2. These results were less encouraging in two larger series. One comes from the prospective ECOG study showing a 37% ORR in 56 patients and the other is retrospective from the French registry and reported a 44% ORR in 36 patients.13, 19 Furthermore, molecular response is rarely obtained and the incidence of relapse following methotrexate is, at least in French experience, estimated at 67%.13 Our series demonstrates that cyclophosphamide used as first-line therapy is effective in T/NK-LGL leukemia, in both neutropenic and anemic patients. ORR and response duration seem encouraging. We recommend only 9–12 months of treatment. It seems sufficient to induce durable remissions and to avoid the complication of myelodysplastic syndromes/acute myeloid leukemia, which although rare is dependent on cumulative dose and length of exposure. For responding patients, tapering dose to 50 mg per day would be a reasonable option. Although recognizing the limits of a retrospective study, we suggest that cyclophosphamide could be an interesting alternative to methotrexate as first-line therapy in LGL leukemia. A prospective study comparing cyclophosphamide to methotrexate as first-line therapy is currently ongoing in France.
References
Loughran TP Jr . Clonal diseases of large granular lymphocytes. Blood 1993; 82: 1–14.
Loughran TP Jr, Kadin ME, Starkebaum G, Abkowitz JL, Clark EA, Disteche C et al. Leukemia of large granular lymphocytes: association with clonal chromosomal abnormalities and autoimmune neutropenia, thrombocytopenia, and hemolytic anemia. Ann Intern Med 1985; 102: 169–175.
Sokol L, Loughran TP Jr . Large granular lymphocyte leukemia. Oncologist 2006; 11: 263–273.
Lamy T, Loughran TP Jr . Clinical features of large granular lymphocyte leukemia. Semin Hematol 2003; 40: 185–195.
Jerez A, Clemente MJ, Makishima H, van Adrichem AJ, Kuusanmäki H, Andersson EI et al. STAT3 mutations unify the pathogenesis of chronic lymphoproliferative disorders of NK cells and T-cell large granular lymphocyte leukemia. Blood 2012; 120: 3048–3057.
Koskela HL, Eldfors S, Ellonen P, Koskela H, LeBlanc F, Peng NgK et al. Somatic STAT3 mutations in large granular lymphocytic leukemia. N Engl J Med 2012; 366: 1905–1913.
Fasan A, Kern W, Grossmann V, Haferlach C, Haferlach T, Schnittger S . STAT3 mutations are highly specific for large granular lymphocytic leukemia. Leukemia 2012; 27: 1598–1600.
Rajala HL, Eldfors S, Kuusanmaki H, van Adrichem AJ, Olson T, Lagström S et al. Discovery of somatic STAT5b mutations in large granular lymphocytic leukemia. Blood 2013; 121: 4541–4550.
Teramo A, Gattazzo C, Passeri F, Lico A, Tasca G, Cabrelle A et al. Intrinsic and extrinsic mechanisms contribute to maintain the JAK/STAT pathway aberrantly activated in T-type large granular lymphocyte leukemia. Blood 2013; 121: 3843–3854.
Loughran TP Jr, Kidd PG, Starkebaum G . Treatment of large granular lymphocyte leukemia with oral low-dose methotrexate. Blood 1994; 84: 2164–2170.
Go RS, Li CY, Tefferi A, Phyliky RL . Acquired pure red cell aplasia associated with lymphoproliferative disease of granular T lymphocytes. Blood 2001; 98: 483–485.
Fujishima N, Sawada K, Hirokawa M, Oshimi K, Sugimoto K, Matsuda A et al. Long-term responses and outcomes following immunosuppressive therapy in large granular lymphocyte leukemia-associated pure red cell aplasia: a Nationwide Cohort Study in Japan for the PRCA Collaborative Study Group. Haematologica 2008; 93: 1555–1559.
Bareau B, Rey J, Hamidou M, Donadieu J, Morcet J, Reman O et al. Analysis of a French cohort of patients with large granular lymphocyte leukemia: a report on 229 cases. Haematologica 2010; 95: 1534–1541.
Lamy T, Loughran TP Jr . How I treat LGL leukemia. Blood 2011; 117: 2764–2774.
Semenzato G, Zambello R, Starkebaum G, Oshimi K, Loughran TP Jr . The lymphoproliferative disease of granular lymphocytes: updated criteria for diagnosis. Blood 1997; 89: 256–260.
Morice WG, Kurtin PJ, Tefferi A, Hanson CA . Distinct bone marrow findings in T-cell granular lymphocytic leukemia revealed by paraffin section immunoperoxidase stains for CD8, TIA-1, and granzyme B. Blood 2002; 99: 268–274.
Dhodapkar MV, Li CY, Lust JA, Tefferi A, Phyliky RL . Clinical spectrum of clonal proliferations of T-large granular lymphocytes: a T-cell clonopathy of undetermined significance? Blood 1994; 84: 1620–1627.
Mohan SR, Clemente MJ, Afable M, Cazzolli HN, Bejanyan N, Wlodarski NW et al. Therapeutic implications of variable expression of CD52 on clonal cytotoxic T cells in CD8+ large granular lymphocyte leukemia. Haematologica 2009; 94: 1407–1414.
Loughran TP Jr, Yao X, Bennett JM, Litzow MR, Evens AM, Tallman MS . Results of a prospective multicenter phase ii study of initial treatment with methotrexate in LGL leukemia (ECOG Protocol E5998). ASH Annual Meeting Abstracts 2010; 116: 702.
Acknowledgements
We thank all clinicians for providing patient data to US, Italian and French LGL Leukemia registry. This work was supported in part by the National Institutes of Health grants CA094872, Associazione Italiana per la Ricerca sul Cancro (AIRC), Cariparo, Cariverona and ADHO (association pour le développement de l’hématologie-Oncologie).
Author contributions
AM and TL designed the study and performed statistical analysis. AM, ZH, LP, BB, OT, AA, KB, RH TPL, RZ, GS and TL were responsible for data collection, data analysis, data interpretation, manuscript preparation, writing and completion and final approval of manuscript. MR and TF participated in biological analysis. All authors approved the final version of the manuscript and the submission.
Author information
Authors and Affiliations
Corresponding author
Ethics declarations
Competing interests
The authors declare no conflict of interest.
Rights and permissions
This work is licensed under a Creative Commons Attribution-NonCommercial-ShareAlike 3.0 Unported License. To view a copy of this license, visit http://creativecommons.org/licenses/by-nc-sa/3.0/
About this article
Cite this article
Moignet, A., Hasanali, Z., Zambello, R. et al. Cyclophosphamide as a first-line therapy in LGL leukemia. Leukemia 28, 1134–1136 (2014). https://doi.org/10.1038/leu.2013.359
Published:
Issue Date:
DOI: https://doi.org/10.1038/leu.2013.359
This article is cited by
-
Protective effect of arbutin against cyclophosphamide-induced oxidative stress, inflammation, and hepatotoxicity via Nrf2/HO-1 pathway in rats
Environmental Science and Pollution Research (2023)
-
Protective effect of alogliptin against cyclophosphamide-induced lung toxicity in rats: Impact on PI3K/Akt/FoxO1 pathway and downstream inflammatory cascades
Cell and Tissue Research (2022)
-
Large Granular Lymphocytic Leukemia: Current State of Diagnosis, Pathogenesis and Treatment
Current Oncology Reports (2022)
-
Immunomodulation in leukemia: cellular aspects of anti-leukemic properties
Clinical and Translational Oncology (2020)
-
Advances in the Diagnosis and Treatment of Large Granular Lymphocytic Leukemia
Current Hematologic Malignancy Reports (2020)